Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
haha thanks catching for that. Maybe 4:1 in the future.
Leo could announce a 1:4 R/S today and we would be on the Nasdaq next week. I think the cost of a reverse split for the retail investors in the long run would be enormous especially in light of the upcoming catalysts. CTIX has the goods to raise share price soon without doing a R/S.
"The application remains pending". No R/S. Leo knows the upcoming catalysts should soon remedy this low price complication.
"52 percent of phase 3 trials are not approved. We have a long road and anything can happen". as said.
They cast doubt out of fear. It's clear this stock is a sleeping giant. Buying after Qualified Infectious Disease Product (QIDP) designation for Brilacidin will look like childs play against uplisting news with following, FDA Brilacidin phase3, B-OM early indications and Kevetrin progressing to phase2/3.
Wow buyers showed up nice to see the love.
I'm thinking that the full p21 report in a scientific journal would be our ticket to ride.
Leo reported in the 10Q that "the Company is saving the full p21 results for an appropriate scientific venue". Would any poster have an idea what the scientific venue would be?
Also great validation in May22 PR: "We could have concluded the trial with the completion of the target enrollment, but we have a novel drug delivering compelling data that we want to push to the limit to best direct the scope of future studies".
"With 40 patients enrolled, Cellceutix feels that it has more than ample data supporting the safety of Kevetrin as well as evidence of possible therapeutic benefits. As such, the Company is moving forward with confidence in preparing documentation for a meeting with the Food and Drug Administration seeking to initiate a Phase 2/3 trial of Kevetrin against a specific type of cancer".
I read the positive posts as validation of the science so far. The leadership PR'd positive Phase2A to date and that's worth positive reviews. IMO to post a negative counter behind a positive report as if looking out for investors is a ruse.
Living on Leo time...Don't worry Bobby we'll get there maybe later then sooner maybe even a little grayer but we'll get there.
Big uplisting news tomorrow?
haha, thanks 123tom.
haha, thanks 123tom.
Thanks Drano. Yes I saw a few familiar names looks like good company. AVXL looks like the real deal being fully reporting.
Thanks Drano. Yes I saw a few familiar names looks like good company. AVXL looks like the real deal being fully reporting.
Hello board. Promising Alzheimer’s data. Bought a position this morning.
Reporting Increased Enrollment in Cellceutix's Clinical Trial of New Cancer Drug and also seeking Phase 2/3 Trial of a specific cancer in the same PR is huge news. The potential to see more then one phase 2/3 trials come out of this phase 1 is possible. This is another huge development for this little biotech. Congratulations to Leo and company and to all us longs.
Yes and I firmly believe they are. This thing will come together and right itself soon I hope.
Cellceutix has a magical pipeline and could have the tiger by the tail if management gets it's act together and just stop the undue over promising, post the milestones when you have one not that your waiting for one. Now we wait for the next promise to come to fruition while the stock price gets pummeled by uncertainty. Brilacidin Phase3 and a surprise partnership could be our salvation I think. The QIDP Designation was a total surprise and sent ctix into new highs. Nice surprise that caught many by surprise. My thoughts have at it.
Are they listed on the Nasdaq?
Agree these conferences while good for showing progression to others in the field do very little for share price if any. But what this Kevetrin poster can do is bolster shareholder confidence. It's what comes out of the event is whats important.
Upcoming material events is what brings in new investors and value. Next comprehensive update to include: Nasdaq uplisting, Increased biomarker p21 measurment at the higher dose showing reactivation of p53(hoping for more patient responses).
Wouldn't it be unlawful for Leo to have heard back from Nasdaq with a big fat no, and then going ahead with an RS without having released prior known material info.
No worries here.
Kevetrin trial was selected out of 6,000 other candidates. I say that carry's a lot potential.
Looking more and more like Big Kahuna is correct. He said: Registration for newly listed shares would impose a quiet period of 30 days from the 27th, or until the SEC declared the registration effective. Hello NASDAQ before the end of the month? Uplist in 9 days?
I'm just hoping we can get on with a phase3 trial soon. I believe the old FDA sees Brilacidin as a completely new technology class and is still trying to get a handle on the defensin-mimetics MOA. Could be wrong but if Brilacidin was a reformulated antibiotic with a known history we would be in phase3 as we post.
My money is on the science and future. I have a tendency of looking at the face value and miss the larger picture. There are the smart people on this board that can read the more subliminal message and know how SEC and FDA works, in which I'm usually lost in the sauce.
The application was sent Feb5. wild4ctix posted his response from Leo stating "We are awaiting their response. They are not giving us a timeline. All they tell our attorneys is that there are a number of applications being reviewed. We are continuing to grow the company until it happen".
After reading multiple posts its pretty easy to tell 3months 10days is long and not part of the norm.
Just not reading Quiet period in Leo's response. Just being honest here.
Awesome. Wow soon have an expanded Kevetrin trial now that ought to get some real attention. Thanks.
"We are pleased with the meticulous care that Dana-Farber and partners have taken in the clinical trial of Kevetrin providing us with exciting data as we move forward with our plans to engage with the FDA for a mid-stage trial in solid tumors in 2015."
Would this be an expanded Phase1 or something more.
What no nails in the coffin. LOL,LOL,LOL,LOL,LOL,LOL,LOL,LOL and so on..
Absolutely agree. A mega Pharma deal would do wonders to boost shareholder value. Having a partnership in the brilacidin development with skin in the game would shoulder in the risk that could quickly crush a tiny biotech.
I hope this company doesn't turn out to be like the singing frog.
Hope springs eternal around these parts. I would never have guessed this stock at this ridiculous price May2015 and no bad news. Why the delays, this will continue the bears march.
The irony that ctix has a developing pipeline what dreams are made of and no buyers.
That uplisting scenario could be huge for ctix buy volume.
Page18 "While the trial is primarily to evaluate safety of repeated cycles of Kevetrin, it is encouraging that some patients have had stabilization of tumor status during treatment. Further, Kevetrin appears to be having the expected effects on p53 in a number of the patients treated, as measured by increases in the levels of the downstream protein p21 biomarker. According to the latest data, over 50% of patients treated have had increases in the p21 marker. In addition, the effect on p53/p21 appears to be dose-dependent, with patients treated in the cohorts receiving 350 and 450 mg/m2 of Kevetrin showing greater increases in levels of p21. At this time, the Company is saving the full p21 results for an appropriate scientific venue". Greater increases of p21 at greater dosage and no DLT. I think ASCO will be huge.
The 10q is first quarter business report ending on 3/31.
23 million needed over next 12months. Partnership has to happen.
Nothing has changed. In fact after viewing the Copenhagen slides I say we are in better shape fundamentally with Brillacidin then what we knew 6 months ago. Cellceutix just like all other biotech wades through a government back and fourth bureaucracy. Leo and Dr Menon just continue to amaze.